On February 19, 2025, the Editorial Office of Ageing and Cancer Research & Treatment (ACRT) had the honor of interviewing Professor Per Thor Straten, Co-Editor-in-Chief of ACRT and a distinguished expert in tumor immunology at Herlev University Hospital in Copenhagen, Denmark. During the interview, Prof. Thor Straten shared valuable insights into his career, the future of T-cell-based immunotherapies, and his vision for the journal.

Interview outline:

Q1. What initially sparked your interest in cancer immunology?

Q2. Your research has significantly advanced our understanding of T-cell-based immunotherapies. What do you see as the next big breakthrough in this field, and how might it address current challenges in treating solid tumors?

Q3. Over the years, you and your team have achieved remarkable breakthroughs in cancer immunology and immunotherapy. Could you share a period of research that you consider the most significant turning point? Are there any memorable experiences from that time?

Q4. What advice would you offer to medical students and researchers aspiring to specialize in cancer immunology? How can they make meaningful contributions to the field and build a career as impactful as yours?

Q5. What aspects of Ageing and Cancer Research & Treatment journal do you find most appealing, and do you have any suggestions for further enhancing its development?

About Prof. Per Thor Straten

Prof. Thor Straten is the Vice-Director of the Center for Cancer Immune Therapy at Herlev University Hospital. He is widely recognized for his work in tumor immunology and cancer immunotherapy, particularly in understanding T-cell responses against cancer and developing novel immunotherapeutic strategies.

We would like to express our sincere gratitude to Prof. Thor Straten for sharing his invaluable insights with us. Inspired and strongly supported by Prof. Thor Straten, we will continue collaborating with outstanding experts to facilitate research in aging and cancer.

Respectfully Submitted by the Editorial Office of ACRT.